Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner

Carcinogenesis

Volumn 35, Issue 4, 2014, Pages 795-806

  Neradugomma, Naveen K ^a   Subramaniam, Dharmalingam ^a,b   Tawfik, Ossama W ^a,b   Goffin, Vincent ^c   Kumar, T Rajendra ^a   Jensen, Roy A ^a,b   Anant, Shrikant ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ALDH 1 PROTEIN; CD 44 PROTEIN; DCLK 1 PROTEIN; HEY 1 PROTEIN; JAGGED1; JANUS KINASE 2; LGR 5 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NOTCH RECEPTOR; NOTCH1 RECEPTOR; PROLACTIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER TISSUE; CELL POPULATION; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STEM CELL; UPREGULATION; WESTERN BLOTTING;

BASE SEQUENCE; COLONIC NEOPLASMS; DNA PRIMERS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; JANUS KINASE 2; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROLACTIN; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84898615062     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt379     Document Type: Article

References (71)

1. Siegel, R. et al. (2013) Cancer statistics, 2013. CA. Cancer J. Clin., 63, 11-30.
2. Majek, O. et al.; GEKID Cancer Survival Working Group. (2013) Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. PLoS One, 8, e68077.
3. Anderson, T.R. et al. (1984) Prolactin's mitogenic action on the pigeon crop-sac mucosal epithelium involves direct and indirect mechanisms. Gen. Comp. Endocrinol., 54, 236-246.
4. Charles, V. et al. (2003) The role of prolactin in mammary carcinoma. Endocr. Rev., 24, 1-27.
5. Das, R. et al. (1997) Prolactin as a mitogen in mammary cells. J. Mammary Gland Biol. Neoplasia, 2, 29-39.
6. Ginsburg, E. et al. (1995) Prolactin synthesis and secretion by human breast cancer cells. Cancer Res., 55, 2591-2595.
7. Dagvadorj, A. et al. (2007) Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology, 148, 3089-3101.
8. Cataldo, L. et al. (2000) Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int. J. Oncol., 17, 1179-1185.
9. Gubbay, O. et al. (2002) Prolactin induces ERK phosphorylation in epithelial and CD56(+) natural killer cells of the human endometrium. J. Clin. Endocrinol. Metab., 87, 2329-2335.
10. Maus, M.V. et al. (1999) Prolactin as a chemoattractant for human breast carcinoma. Endocrinology, 140, 5447-5450.
11. Perks, C.M. et al. (2004) Prolactin acts as a potent survival factor for human breast cancer cell lines. Br. J. Cancer, 91, 305-311.
12. Buckley, A.R. et al. (1985) Prolactin is a tumor promoter in rat liver. Life Sci., 37, 2569-2575.
13. Wang, W.W. et al. (2013) Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma. PLoS One, 8, e68904.
14. Clendenen, T.V. et al. (2013) Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes Control, 24, 741-748.
15. Levina, V.V. et al. (2009) Biological significance of prolactin in gynecologic cancers. Cancer Res., 69, 5226-5233.
16. Mendoza-Romo, M.A. et al. (2010) The role of prolactin in prostate cancer. Rev. Mex. Urol., 70, 55-60.
17. Rouet, V. et al. (2010) Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc. Natl. Acad. Sci. U. S. A., 107, 15199-15204.
18. Ruffion, A. et al. (2003) The survival effect of prolactin on PC3 prostate cancer cells. Eur. Urol., 43, 301-308.
19. Van Coppenolle, F. et al. (2001) Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am. J. Physiol. Endocrinol. Metab., 280, E120-E129.
20. Nagano, M. et al. (1995) Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am. J. Physiol., 268(3 Pt 1), G431-G442.
21. Deachapunya, C. et al. (2012) Site-specific regulation of ion transport by prolactin in rat colon epithelium. Am. J. Physiol. Gastrointest. Liver Physiol., 302, G1199-G1206.
22. Teerapornpuntakit, J. et al. (2012) Proliferation and mRNA expression of absorptive villous cell markers and mineral transporters in prolactinexposed IEC-6 intestinal crypt cells. Cell Biochem. Funct., 30, 320-327.
23. Bhatavdekar, J.M. et al. (1992) Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. Br. J. Cancer, 66, 977-980.
24. Bhatavdekar, J.M. et al. (2001) Ectopic production of prolactin by colorectal adenocarcinoma. Dis. Colon Rectum, 44, 119-127.
25. Soroush, A.R. et al. (2004) Plasma prolactin in patients with colorectal cancer. BMC Cancer, 4, 97.
26. Ilan, Y. et al. (1995) Plasma and tumor prolactin in colorectal cancer patients. Dig. Dis. Sci., 40, 2010-2015.
27. Otte, J.M. et al. (2003) Expression of functional prolactin and its receptor in human colorectal cancer. Int. J. Colorectal Dis., 18, 86-94.
28. Bonnet, D. et al. (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med., 3, 730-737.
29. Nakanishi, Y. et al. (2013) Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat. Genet., 45, 98-103.
30. Gagliardi, G. et al. (2012) Immunolocalization of DCAMKL-1, a putative intestinal stem cell marker, in normal colonic tissue. Pathol. Res. Pract., 208, 475-479.
31. May, R. et al. (2009) Doublecortin and CaM kinase-like-1 and leucine-richrepeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells, 27, 2571-2579.
32. Barker, N. et al. (2012) Lgr5(+ve) stem/progenitor cells contribute to nephron formation during kidney development. Cell Rep., 2, 540-552.
33. Barker, N. et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature, 449, 1003-1007.
34. Muñoz, J. et al. (2012) The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. EMBO J., 31, 3079-3091.
35. Sato, T. et al. (2009) Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature, 459, 262-265.
36. Chaffer, C.L. et al. (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. U. S. A., 108, 7950-7955.
37. Montgomery, R.K. et al. (2008) Small intestinal stem cell markers. J. Anat., 213, 52-58.
38. Januchowski, R. et al. (2013) The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed. Pharmacother., 67, 669-680.
39. Kvinlaug, B.T. et al. (2007) Targeting cancer stem cells. Expert Opin. Ther. Targets, 11, 915-927.
40. Walker, T.L. et al. (2012) Prolactin stimulates precursor cells in the adult mouse hippocampus. PLoS One, 7, e44371.
41. Dillner, K. et al. (2003) Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology, 144, 4955-4966.
42. Kopan, R. et al. (1996) The Notch pathway: democracy and aristocracy in the selection of cell fate. Curr. Opin. Neurobiol., 6, 594-601.
43. Sander, G.R. et al. (2004) Expression of notch receptors and ligands in the adult gut. J. Histochem. Cytochem., 52, 509-516.
44. Fre, S. et al. (2005) Notch signals control the fate of immature progenitor cells in the intestine. Nature, 435, 964-968.
45. Nickoloff, B.J. et al. (2003) Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene, 22, 6598-6608.
46. Schroeter, E.H. et al. (1998) Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature, 393, 382-386.
47. De Strooper, B. et al. (1999) A presenilin-1-dependent gamma-secretaselike protease mediates release of Notch intracellular domain. Nature, 398, 518-522.
48. Lai, E.C. (2004) Notch signaling: control of cell communication and cell fate. Development, 131, 965-973.
49. Goh, F. et al. (2009) Selective induction of the Notch ligand Jagged-1 in macrophages by soluble egg antigen from Schistosoma mansoni involves ERK signalling. Immunology, 127, 326-337.
50. Subramaniam, D. et al. (2012) Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One, 7, e30590.
51. Besser, D. et al. (1999) A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol. Cell. Biol., 19, 1401-1409.
52. Curry, C.L. et al. (2005) Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene, 24, 6333-6344.
53. Wang, J. et al. (2012) Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients. J. Gastrointest. Cancer, 43, 444-455.
54. Singh, S.K. et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res., 63, 5821-5828.
55. Liu, J. et al. (2013) Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties. Int. J. Oncol., 42, 453-459.
56. Nie, Z. et al. (2012) c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell, 151, 68-79.
57. Fortini, M.E. (2009) Notch signaling: the core pathway and its posttranslational regulation. Dev. Cell, 16, 633-647.
58. Dusanter-Fourt, I. et al. (1992) Expression of prolactin (PRL) receptor gene and PRL-binding sites in rabbit intestinal epithelial cells. Endocrinology, 130, 2877-2882.
59. Kagnoff, M.F. (1993) Immunology of the intestinal tract. Gastroenterology, 105, 1275-1280.
60. Ozarda, A.T. (1983) Prolactin-secreting tumors. J. Surg. Oncol., 22, 9-10.
61. Stanisic, T.H. et al. (1986) Prolactin secreting renal cell carcinoma. J. Urol., 136, 85-86.
62. Hoffmann, W.H. et al. (1987) Ectopic prolactin production from gonadoblastoma. Cancer., 60, 2690-2695.
63. MUHLBOCK, O. et al. (1959) Induction of mammary cancer in mice without the mammary tumor agent by isografts of hypophyses. Cancer Res., 19, 402-412.
64. Welsch, C.W. et al. (1977) Prolactin and murine mammary tumorigenesis: a review. Cancer Res., 37, 951-963.
65. Harbaum, L. et al. (2010) Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases. Mod. Pathol., 23, 961-971.
66. Bole-Feysot, C. et al. (1998) Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev., 19, 225-268.
67. Yu-Lee, L.Y. et al. (1998) Lactogenic hormone signal transduction. Biol. Reprod., 58, 295-301.
68. Krasilnikov, M. et al. (2003) ERK and PI3K negatively regulate STATtranscriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene, 22, 4092-4101.
69. Sarah, R. et al. (2009) Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol. Cancer Res., 7, 966-976.
70. Sarah, R. et al. (2013) STAT5 Outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol. Cell Biol., 33, 2879-2890.
71. Sureban, S.M. et al. (2008) Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology, 134, 1448-1458.